Peptidream collaborates with Genentech on discovery and development of peptide-radioisotope drug conjugates
Sep. 20, 2023
Peptidream Inc. has entered into a new multitarget collaboration and license agreement with Genentech, a member of the Roche Group, focused on the discovery and development of novel macrocyclic peptide-radioisotope drug conjugates.